AR and prostate carcinoma: Finally, GPRC6A mediates the non-genomic, rapid signaling responses to testosterone [26], leading to activation of PI3K/Akt pathways that are implicated in androgen receptor (AR)-independent progression and therapeutic resistance of prostate cancer [27].